Navigation Links
Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
Date:10/9/2007

Phase 2 Drug Candidate Protects the Ocular Surface Following Exposure to

Controlled Adverse Environment, Reduces Dry Eye Symptoms

LAGUNA HILLS, Calif., Oct. 9 /PRNewswire/ -- Alacrity Biosciences today announced that its dry eye treatment, ALTY-0501, demonstrated statistically significant advantages over vehicle in its ability to control signs and symptoms of dry eye in a Phase 2 study.

The Phase 2 study utilized the controlled adverse environment (CAE) chamber to measure dry eye patients' ability to withstand a stressful drying environment on the eye, and patient diaries to measure the severity of their dry eye symptoms over the course of the study. Patients were randomized to receive ALTY-0501 or its vehicle four times each day over the course of a 56 day study.

Patients who received ALTY-0501 demonstrated statistically significantly lower scores following CAE exposure for fluorescein staining of the total cornea-a measure of damage to the ocular surface-than those who received vehicle (p < 0.05) on day 28. Statistically significant differences from vehicle were also observed with total corneal and conjunctival staining (p < 0.05), superior corneal staining (p < 0.001) and nasal conjunctival staining (p < 0.05).

ALTY-0501 also demonstrated statistically significant advantages compared to vehicle in the patient diary scores measuring the severity of dry eye symptoms over the 56-day study period. Specifically, patient diary scores reflected statistically significantly lower scores for the symptoms of burning (p < 0.0001), stinging (p < 0.0001), and grittiness (p < 0.0001) in the active treated group.

"We have strong evidence that ALTY-0501 can help control patient signs and symptoms by maintaining the epithelial barrier on the surface of the eye," said David F. Power, Alacrity's president and CEO. "We plan to discuss the Phase 2 data and confirm our Phase 2b/3 strategy with the FDA in the fourth quarter of 2007. Our in
'/>"/>

SOURCE Alacrity Biosciences
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
4. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
5. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
9. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
10. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
11. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 25, 2014 Reinforcing its commitment ... (NYSE: PHG AEX: PHIA) today ... Administration (FDA) for its IQon Spectral CT , ... first-of-its kind technology adds a new dimension to Computed ... ability to characterize structures based on their material content ...
(Date:11/26/2014)... Pa. , Nov. 25, 2014  Unilife Corporation ... of injectable drug delivery systems, today announced that its ... to present at the Piper Jaffray 26th Annual Healthcare ... a.m. EST on Tuesday, December 2, 2014. ... Internet as a "live" listen only Webcast. To listen, ...
(Date:11/26/2014)... 25, 2014 Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... presentations at two upcoming investor conferences.  , 31 ... on Tuesday, December 2, 2014 at 6:45 a.m. EST / ... head of EUSA International, will provide an overview of the company ... Annual Piper Jaffray Healthcare Conference in New York, NY ...
Breaking Medicine Technology:Philips receives FDA 510(k) clearance for IQon Spectral CT 2Philips receives FDA 510(k) clearance for IQon Spectral CT 3Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Jazz Pharmaceuticals Announces Participation in Two Investor Conferences 2
... Spencer Inc. (NYSE: CSA ) announced today ... of $0.10 per common share payable on October 20, 2010 ... covers the third quarter of 2010.   ... Spencer Inc. (NYSE: CSA ) is a fully-integrated, ...
... Pharmaceutical Company (NYSE:  KVa/KVb) announced today that it has ... ("FDA") of the successful completion of an inspection of ... product to market.  Under the Company,s Consent Decree, successful ... facilities are expected to be required before K-V is ...
Cached Medicine Technology:Cogdell Spencer Inc. Declares Quarterly Dividend 2K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 2K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 3K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 4K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 5K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 6K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 7K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 8
(Date:11/27/2014)... babies and young children don,t need medicines if they ... says. Over-the-counter (OTC) cold and cough medicine should ... they could cause serious and potentially deadly side effects, ... colds a year, but children get them more often. ... give them pain relievers, decongestants and other medicines, but ...
(Date:11/27/2014)... November 27, 2014 The founders of VIM ... comfortable and high functioning compression socks, are proud to announce ... use an innovative Gradient Pressure (TM) knitting technology that is ... VIM & VIGR’s commitment to adding flair and style to ... functional recently caught the eye of a writer at ...
(Date:11/27/2014)... 27, 2014 Two international trainers and ... procedure will help one person with significant needs but ... Jivraj and Dr. Mamaly Reshad of the Anacapa Dental ... launched a website devoted to helping dentist learn about ... website would be devoted to helping a patient who ...
(Date:11/27/2014)... California (PRWEB) November 27, 2014 Developers and ... a new plugin entitled ProPip, taking FCPX to the next ... picture effect with a few clicks of a mouse,” said ... time saver that our users will appreciate.” , With ProPip ... customization leaving the possibilities truly endless. ProPip is great for ...
(Date:11/27/2014)... Philadelphia, PA (PRWEB) November 27, 2014 ... alongside volunteer Aria Health employees, prepared and donated ... to the Lutheran Settlement House , a non-profit, ... and families living in Philadelphia. The dinners were ... Settlement House Senior Center, and distributed to vulnerable ...
Breaking Medicine News(10 mins):Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 2Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 3Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 4Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 5Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 3Health News:Aria Health Prepares and Donates 200 Thanksgiving Dinners 2
... PROVIDENCE, R.I. A new nationwide clinician survey provides ... or treatment as usual for nonepileptic seizures (NES), laying ... treatments for this neuropsychiatric disorder. , There is ... resembles an epileptic seizure but is not caused by ...
... highlight how innovative solutions based on the Microsoft platform solve ... key industry challenges., ... Health & Life Sciences Developer and ... customers and industry partners speaking on the newest solutions and ...
... Meeting on April 22, 2008, the Centers for Medicare ... the establishment of a Healthcare Common Procedure Coding System ... the HCPCS is a standardized coding system that is ... in the Current Procedural Terminology (CPT) coding system assigned ...
... CSC to bundle healthcare services around intellectual property ... - Deward Watts appointed to lead practice ... Project Accelerate strategy, FALLS CHURCH, Va., April 21 ... of the company,s new,Healthcare Sector, a dedicated vertical business unit ...
... Milestone,Scientific Inc. (OTC Bulletin Board: MLSS), the recognized ... Device &,Diagnostic Industry (MD&DI) magazine has distinguished the ... Design Excellence Award (MDEA) in the,"dental instruments, equipment ... receive an MDEA this year, Milestone,s STA System ...
... MADISON, N.J., April 21 Quest Diagnostics,Incorporated (NYSE: ... and services, announced that for the first quarter,ended March ... $0.72 per diluted share, compared to $108 million, or ... Included in the results for the first,quarter of 2007 ...
Cached Medicine News:Health News:Survey offers first-ever look at treatment practices for nonepileptic seizures 2Health News:Microsoft Health & Life Sciences Developer and Solutions Conference to Feature the Latest Microsoft-Based Software Solutions 2Health News:Medicare to consider public opinion about medical maggots 2Health News:Medicare to consider public opinion about medical maggots 3Health News:CSC Launches Global Healthcare Sector 2Health News:CSC Launches Global Healthcare Sector 3Health News:Milestone Scientific's STA(TM) System Wins 2008 Medical Design Excellence Award 2Health News:Milestone Scientific's STA(TM) System Wins 2008 Medical Design Excellence Award 3Health News:Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008 2Health News:Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008 3Health News:Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008 4Health News:Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008 5Health News:Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008 6Health News:Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008 7Health News:Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008 8Health News:Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008 9Health News:Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008 10Health News:Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008 11
The Telescopic Plate Spacer (TPS - C) Implants is an expandable titanium spacer designed to stabilize the spine following corpectomy/ vertebrectomy procedures....
... generation interbody fusion device. Rhakoss implants ... alternative to titanium/carbon fiber cages and ... the best features of first generation ... disadvantages of current available materials, such ...
Fortitude as a unique complement to the spinal concepts family of products....
As a unique complement to the spinal concepts family of products....
Medicine Products: